- Home
- INTA vs ACAD Comparison
INTA vs ACAD Comparison
Compare INTA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTA
- ACAD
- Stock Information
- Founded
- INTA 2000
- ACAD 1993
- Country
- INTA United States
- ACAD United States
- Employees
- INTA N/A
- ACAD N/A
- Industry
- INTA Computer Software: Prepackaged Software
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- INTA Technology
- ACAD Health Care
- Exchange
- INTA Nasdaq
- ACAD Nasdaq
- Market Cap
- INTA 3.1B
- ACAD 3.5B
- IPO Year
- INTA 2021
- ACAD 2004
- Fundamental
- Price
- INTA $39.91
- ACAD $22.00
- Analyst Decision
- INTA Buy
- ACAD Buy
- Analyst Count
- INTA 9
- ACAD 21
- Target Price
- INTA $62.00
- ACAD $29.43
- AVG Volume (30 Days)
- INTA 695.6K
- ACAD 2.0M
- Earning Date
- INTA 11-04-2025
- ACAD 11-05-2025
- Dividend Yield
- INTA N/A
- ACAD N/A
- EPS Growth
- INTA N/A
- ACAD 615.00
- EPS
- INTA N/A
- ACAD 1.33
- Revenue
- INTA $504,120,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- INTA $15.18
- ACAD $14.01
- Revenue Next Year
- INTA $13.51
- ACAD $12.00
- P/E Ratio
- INTA N/A
- ACAD $16.61
- Revenue Growth
- INTA 17.09
- ACAD 14.41
- 52 Week Low
- INTA $35.51
- ACAD $13.40
- 52 Week High
- INTA $77.74
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- INTA 49.65
- ACAD 51.82
- Support Level
- INTA $36.12
- ACAD $20.33
- Resistance Level
- INTA $40.09
- ACAD $22.10
- Average True Range (ATR)
- INTA 1.16
- ACAD 0.81
- MACD
- INTA 0.36
- ACAD 0.23
- Stochastic Oscillator
- INTA 92.46
- ACAD 92.40
About INTA Intapp Inc.
Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital,g, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.